Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?


Sumbul A. T. , Disel U., Sezgin N. , Sezer A., Kose F., Besen A. A. , et al.

MEDICAL SCIENCE MONITOR, cilt.20, ss.428-433, 2014 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 20
  • Basım Tarihi: 2014
  • Doi Numarası: 10.12659/msm.889945
  • Dergi Adı: MEDICAL SCIENCE MONITOR
  • Sayfa Sayısı: ss.428-433

Özet

Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy.